Skip to main content
. 2023 Jan 12;25:4. doi: 10.1186/s13058-022-01601-4

Table 2.

Univariate and multivariate analyses of progression-free survival in the exploratory cohort

Index Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age
 ≥ 65 years old 0.746 (0.433–1.285) 0.290
 < 65 years old Reference
Race
 White Reference
 Others 0.786 (0.109–5.662) 0.811
Initial stage
 III–IV 0.785 (0.515–1.197) 0.261
 Others Reference
Recurrence type
 Newly diagnosed 0.664 (0.425–1.038) 0.072
 Others Reference
Disease-free interval
 Newly metastatic disease 0.625 (0.404–0.966) 0.035 0.574 (0.367–0.898) 0.015
 Others Reference Reference
Disease site
 Visceral 1.771 (1.129–2.778) 0.013 1.847 (1.167–2.925) 0.009
 Nonvisceral Reference Reference
 Bone-only metastasis 0.683 (0.385–1.211) 0.192
 Others Reference
Number of disease sites
 ≥ 3 1.609 (1.055–2.455) 0.027 1.579 (1.017–2.450) 0.042
 1, 2 Reference Reference
Derived neutrophil-to-lymphocyte ratioa
  ≥ 1.04 3.369 (2.134–5.320)  < 0.001 3.314 (2.090–5.256)  < 0.001
 < 1.04 Reference Reference

CI, confidence interval; HR, hazard ratio

aMeasured at cycle 2 day 1